ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
| Revenue (TTM) | $519.15M |
| Gross Profit (TTM) | $355.76M |
| EBITDA | $240.70M |
| Operating Margin | 48.00% |
| Return on Equity | 41.90% |
| Return on Assets | 22.40% |
| Revenue/Share (TTM) | $2.24 |
| Book Value | $1.97 |
| Price-to-Book | 6.69 |
| Price-to-Sales (TTM) | 5.44 |
| EV/Revenue | 5.8 |
| EV/EBITDA | 11.92 |
| Quarterly Earnings Growth (YoY) | 46.70% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $221.85M |
| Float | $217.57M |
| % Insiders | 1.99% |
| % Institutions | 93.45% |
Volatility is currently expanding
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2026 Adjusted Net Income ( 1) of $51.1 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year 3Q 2026 Adjusted Basic EPS ( 2) of $0.23, Increasing 44% Year-over-Year 3Q 2026 Adjusted EBITDA ( 3 ) of $77.3 Million, Increasing 32% Year-over-Year 3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year-over-Year Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial Differentiation Robust Cash Generation, Operating Leverage and Share Repurchases Support Stockholder Value Encouraging Regulatory Feedback Received from SG-001 Pre-IND Meeting Package Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook RAMSEY, N.J. and BOCA RATON, Fla.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ADMA and any ticker you trade — then tracks every position and per-strategy win rate.
